GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Biogen Inc (HAM:IDP) » Definitions » Inventories, Finished Goods

Biogen (HAM:IDP) Inventories, Finished Goods

: €0 Mil (As of Dec. 2023)
View and export this data going back to 2001. Start your Free Trial

Biogen's quarterly finished goods increased from Jun. 2023 (€180 Mil) to Sep. 2023 (€296 Mil) but then declined from Sep. 2023 (€296 Mil) to Dec. 2023 (€0 Mil).

Biogen's annual finished goods increased from Dec. 2021 (€166 Mil) to Dec. 2022 (€189 Mil) but then declined from Dec. 2022 (€189 Mil) to Dec. 2023 (€0 Mil).


Biogen Inventories, Finished Goods Historical Data

The historical data trend for Biogen's Inventories, Finished Goods can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biogen Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Inventories, Finished Goods
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 157.05 171.96 166.29 189.18 -

Biogen Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Inventories, Finished Goods Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 189.18 192.31 179.80 296.19 -

Biogen Inventories, Finished Goods Calculation

The products in a manufacturer's inventory that are completed and are waiting to be sold.


Biogen (HAM:IDP) Business Description

Industry
Address
225 Binney Street, Cambridge, MA, USA, 02142
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel multiple sclerosis drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is copromoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with Sobi) were spun off as part of Bioverativ in 2017. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (post-partum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology-related fields.

Biogen (HAM:IDP) Headlines

No Headlines